Quale terapia per i pazienti anziani con carcinoma della prostata ormonoresistente?

Translated title of the contribution: Which therapy for elderly patients with hormone-refractory prostatic carcinoma?

Research output: Contribution to journalArticlepeer-review

Abstract

Nearly all patients with metastatic prostate cancer will develop hormone-refractory disease that results in progressive clinical deterioration and ultimately death. Still today the choice of the best treatment for this neoplasm represents a challenge for geriatric oncologists. In this scenario a comprehensive geriatric assessment plays a key role. In fact, patients with a good performance status and without comorbidities may be suitable for a docetaxel-based and vinorelbine-based first and second line chemotherapy, respectively. On the contrary subjects with a poor performance status and with an ADL or IADL dependance can receive only a palliative treatment with the aim of preserve their quality of life.

Translated title of the contributionWhich therapy for elderly patients with hormone-refractory prostatic carcinoma?
Original languageItalian
Pages (from-to)92-102
Number of pages11
JournalGeriatric and Medical Intelligence
Volume14
Issue number2
Publication statusPublished - Jul 2005

ASJC Scopus subject areas

  • Geriatrics and Gerontology

Fingerprint Dive into the research topics of 'Which therapy for elderly patients with hormone-refractory prostatic carcinoma?'. Together they form a unique fingerprint.

Cite this